RXRX NASDAQ
Credit Risk of going bust: lower than 55% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99.6%), Recursion Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $61.9M against a stock market value of $2.17B.
Distance to default 5.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.9M (short-term plus half of long-term), stock volatility 72.9%; Altman Z'' -3.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Salt Lake City, UT 84101
US
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Borgeson Blake | S-Sale | 50,000 | $4.84 | 2026-10-06 |
| HERSHBERG ROBERT | M-Exempt | 25,000 | $2.22 | 2026-10-06 |
| HERSHBERG ROBERT | S-Sale | 25,000 | $5.00 | 2026-10-06 |
| HERSHBERG ROBERT | M-Exempt | 25,000 | $2.22 | 2026-10-06 |
| Dar Zavain | A-Award | 4,607 | — | 2026-10-01 |